BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16624620)

  • 1. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes.
    Arnold GS; Sasser AK; Stachler MD; Bartlett JS
    Mol Ther; 2006 Jul; 14(1):97-106. PubMed ID: 16624620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector.
    Campos SK; Parrott MB; Barry MA
    Mol Ther; 2004 Jun; 9(6):942-54. PubMed ID: 15194061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells.
    Stachler MD; Bartlett JS
    Gene Ther; 2006 Jun; 13(11):926-31. PubMed ID: 16482202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting.
    Campos SK; Barry MA
    Virology; 2006 Jun; 349(2):453-62. PubMed ID: 16504233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adeno-associated virus serotypes: vector toolkit for human gene therapy.
    Wu Z; Asokan A; Samulski RJ
    Mol Ther; 2006 Sep; 14(3):316-27. PubMed ID: 16824801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of vaccinia virus using biotin-avidin viral coating and biotinylated antibodies.
    Purow B; Staveley-O'Carroll K
    J Surg Res; 2005 Jan; 123(1):49-54. PubMed ID: 15652950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in adeno-associated virus vector technology.
    Büning H; Perabo L; Coutelle O; Quadt-Humme S; Hallek M
    J Gene Med; 2008 Jul; 10(7):717-33. PubMed ID: 18452237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo.
    Palomeque J; Chemaly ER; Colosi P; Wellman JA; Zhou S; Del Monte F; Hajjar RJ
    Gene Ther; 2007 Jul; 14(13):989-97. PubMed ID: 17251988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations.
    Boucas J; Lux K; Huber A; Schievenbusch S; von Freyend MJ; Perabo L; Quadt-Humme S; Odenthal M; Hallek M; Büning H
    J Gene Med; 2009 Dec; 11(12):1103-13. PubMed ID: 19777441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification.
    Parrott MB; Adams KE; Mercier GT; Mok H; Campos SK; Barry MA
    Mol Ther; 2003 Oct; 8(4):688-700. PubMed ID: 14529842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAV vectors for hemophilia B gene therapy.
    Chao H; Walsh CE
    Mt Sinai J Med; 2004 Oct; 71(5):305-13. PubMed ID: 15543431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase.
    Stachler MD; Chen I; Ting AY; Bartlett JS
    Mol Ther; 2008 Aug; 16(8):1467-73. PubMed ID: 18560418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of targeted AAV2 vectors from novel virus display libraries.
    Waterkamp DA; Müller OJ; Ying Y; Trepel M; Kleinschmidt JA
    J Gene Med; 2006 Nov; 8(11):1307-19. PubMed ID: 16955542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors.
    Müller OJ; Kaul F; Weitzman MD; Pasqualini R; Arap W; Kleinschmidt JA; Trepel M
    Nat Biotechnol; 2003 Sep; 21(9):1040-6. PubMed ID: 12897791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting and purification of metabolically biotinylated baculovirus.
    Kaikkonen MU; Viholainen JI; Närvänen A; Ylä-Herttuala S; Airenne KJ
    Hum Gene Ther; 2008 Jun; 19(6):589-600. PubMed ID: 18479188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of adeno-associated viral vectors in insect cells using triple infection: optimization of baculovirus concentration ratios.
    Aucoin MG; Perrier M; Kamen AA
    Biotechnol Bioeng; 2006 Dec; 95(6):1081-92. PubMed ID: 16952153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies.
    Kuck D; Kern A; Kleinschmidt JA
    J Virol Methods; 2007 Mar; 140(1-2):17-24. PubMed ID: 17126418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altering AAV tropism with mosaic viral capsids.
    Gigout L; Rebollo P; Clement N; Warrington KH; Muzyczka N; Linden RM; Weber T
    Mol Ther; 2005 Jun; 11(6):856-65. PubMed ID: 15922956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids.
    Grifman M; Trepel M; Speece P; Gilbert LB; Arap W; Pasqualini R; Weitzman MD
    Mol Ther; 2001 Jun; 3(6):964-75. PubMed ID: 11407911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avidin-biotin interaction mediated peptide assemblies as efficient gene delivery vectors for cancer therapy.
    Qu W; Chen WH; Kuang Y; Zeng X; Cheng SX; Zhou X; Zhuo RX; Zhang XZ
    Mol Pharm; 2013 Jan; 10(1):261-9. PubMed ID: 23146022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.